Literature DB >> 19657562

Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia.

G Onder1, C Della Vedova, F Landi.   

Abstract

Loss of physical function in older adults may be, at least in part, explained by sarcopenia, a phenomenon characterized by a reduction in number and size of muscle fibres and by increase in interstitial fat and connective tissue. Lifestyle intervention (i.e. physical activity and nutrition) have shown to impact on sarcopenia. However, several drugs were suggested, with various levels of scientific evidence, to have an impact on muscle outcomes. In this study we reviewed the effect of six classes of drugs on sarcopenia and muscular outcomes in older adults. We decided to focus our review on two commonly drugs which have recently showed promising effects on muscular outcomes in older adults (ACE inhibitors and statins) and on four drugs whose effect on skeletal muscle was already largely studied (creatine, Growth Hormone, testosterone, estrogens and tibolone).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19657562     DOI: 10.1007/s12603-009-0209-4

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  145 in total

1.  ACE ID genotype and the muscle strength and size response to unilateral resistance training.

Authors:  Linda S Pescatello; Matthew A Kostek; Heather Gordish-Dressman; Paul D Thompson; Richard L Seip; Thomas B Price; Theodore J Angelopoulos; Priscilla M Clarkson; Paul M Gordon; Niall M Moyna; Paul S Visich; Robert F Zoeller; Joseph M Devaney; Eric P Hoffman
Journal:  Med Sci Sports Exerc       Date:  2006-06       Impact factor: 5.411

2.  The influence of menopause and hormonal replacement therapy on body cell mass and body fat mass.

Authors:  J F Aloia; A Vaswani; L Russo; M Sheehan; E Flaster
Journal:  Am J Obstet Gynecol       Date:  1995-03       Impact factor: 8.661

3.  Androgen treatment and muscle strength in elderly men: A meta-analysis.

Authors:  Kenneth J Ottenbacher; Margaret E Ottenbacher; Allison J Ottenbacher; Ana Alfaro Acha; Glenn V Ostir
Journal:  J Am Geriatr Soc       Date:  2006-11       Impact factor: 5.562

4.  Estrogen receptor alpha mRNA in human skeletal muscles.

Authors:  Sophie Lemoine; Pascale Granier; Christophe Tiffoche; Francoise Rannou-Bekono; Marie-Lise Thieulant; Paul Delamarche
Journal:  Med Sci Sports Exerc       Date:  2003-03       Impact factor: 5.411

5.  Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.

Authors:  Stephanie T Page; John K Amory; F Dubois Bowman; Bradley D Anawalt; Alvin M Matsumoto; William J Bremner; J Lisa Tenover
Journal:  J Clin Endocrinol Metab       Date:  2004-11-30       Impact factor: 5.958

6.  Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women.

Authors:  W Hänggi; K Lippuner; P Jaeger; M H Birkhäuser; F F Horber
Journal:  Clin Endocrinol (Oxf)       Date:  1998-06       Impact factor: 3.478

Review 7.  Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection.

Authors:  W W Parmley
Journal:  Am J Med       Date:  1998-07-06       Impact factor: 4.965

8.  Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial.

Authors:  Marielle H Emmelot-Vonk; Harald J J Verhaar; Hamid R Nakhai Pour; André Aleman; Tycho M T W Lock; J L H Ruud Bosch; Diederick E Grobbee; Yvonne T van der Schouw
Journal:  JAMA       Date:  2008-01-02       Impact factor: 56.272

9.  Angiotensin I-converting enzyme (ACE) gene polymorphism in relation to physical performance, cognition and survival--a follow-up study of elderly Danish twins.

Authors:  Henrik Frederiksen; David Gaist; Lise Bathum; Kjeld Andersen; Matt McGue; James W Vaupel; Kaare Christensen
Journal:  Ann Epidemiol       Date:  2003-01       Impact factor: 3.797

10.  The I allele of the angiotensin-converting enzyme gene is associated with an increased percentage of slow-twitch type I fibers in human skeletal muscle.

Authors:  B Zhang; H Tanaka; N Shono; S Miura; A Kiyonaga; M Shindo; K Saku
Journal:  Clin Genet       Date:  2003-02       Impact factor: 4.438

View more
  11 in total

1.  Sarcopenia: biomarkers and imaging (International Conference on Sarcopenia research).

Authors:  G Abellan van Kan; J M Cderbaum; M Cesari; P Dahinden; R G Fariello; R A Fielding; B H Goodpaster; S Hettwer; M Isaac; D Laurent; J E Morley; M Pahor; D Rooks; R Roubenoff; S B Rutkove; A Shaheen; S Vamvakas; J W Vrijbloed; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-12       Impact factor: 4.075

Review 2.  Nutritional recommendations for the management of sarcopenia.

Authors:  John E Morley; Josep M Argiles; William J Evans; Shalender Bhasin; David Cella; Nicolaas E P Deutz; Wolfram Doehner; Ken C H Fearon; Luigi Ferrucci; Marc K Hellerstein; Kamyar Kalantar-Zadeh; Herbert Lochs; Neil MacDonald; Kathleen Mulligan; Maurizio Muscaritoli; Piotr Ponikowski; Mary Ellen Posthauer; Filippo Rossi Fanelli; Morrie Schambelan; Annemie M W J Schols; Michael W Schuster; Stefan D Anker
Journal:  J Am Med Dir Assoc       Date:  2010-07       Impact factor: 4.669

Review 3.  Selecting Potential Pharmacological Interventions in Sarcopenia.

Authors:  Amanda J Kilsby; Avan A Sayer; Miles D Witham
Journal:  Drugs Aging       Date:  2017-04       Impact factor: 3.923

4.  Effect of Antihypertensive and Statin Medication Use on Muscle Performance in Community-Dwelling Older Adults Performing Strength Training.

Authors:  Mohammad Alturki; Keliane Liberman; Andreas Delaere; Liza De Dobbeleer; Veerle Knoop; Tony Mets; Siddhartha Lieten; Bert Bravenboer; Ingo Beyer; Ivan Bautmans
Journal:  Drugs Aging       Date:  2021-02-05       Impact factor: 3.923

5.  Gonadal status and physical performance in older men.

Authors:  Marcello Maggio; Gian Paolo Ceda; Fulvio Lauretani; Stefania Bandinelli; Earl Jeffrey Metter; Jack M Guralnik; Shehzad Basaria; Chiara Cattabiani; Michele Luci; Elisabetta Dall'Aglio; Alessandro Vignali; Riccardo Volpi; Giorgio Valenti; Luigi Ferrucci
Journal:  Aging Male       Date:  2010-10-12       Impact factor: 5.892

Review 6.  Effect of Angiotensin-Converting Enzyme Inhibitors on Physical Function in Elderly Subjects: A Systematic Review and Meta-Analysis.

Authors:  Ling-shan Zhou; Ling-jie Xu; Xue-qing Wang; Yi-huan Huang; Qian Xiao
Journal:  Drugs Aging       Date:  2015-09       Impact factor: 3.923

7.  Carla Task Force on Sarcopenia: propositions for clinical trials.

Authors:  G Abellan van Kan; E André; H A Bischoff Ferrari; Y Boirie; G Onder; M Pahor; P Ritz; Y Rolland; C Sampaio; S Studenski; M Visser; B Vellas
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

8.  Comparative Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Response to a Physical Activity Intervention in Older Adults: Results From the Lifestyle Interventions and Independence for Elders Study.

Authors:  Joshua D Brown; Steven M Smith; Elsa S Strotmeyer; Stephen B Kritchevsky; Thomas M Gill; Steven N Blair; Roger A Fielding; Thomas W Buford; Marco Pahor; Todd M Manini
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-04-17       Impact factor: 6.053

9.  A validation of the application of D(2)O stable isotope tracer techniques for monitoring day-to-day changes in muscle protein subfraction synthesis in humans.

Authors:  Daniel J Wilkinson; Martino V Franchi; Matthew S Brook; Marco V Narici; John P Williams; William K Mitchell; Nathaniel J Szewczyk; Paul L Greenhaff; Philip J Atherton; Kenneth Smith
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-12-31       Impact factor: 4.310

Review 10.  Live strong and prosper: the importance of skeletal muscle strength for healthy ageing.

Authors:  Michael McLeod; Leigh Breen; D Lee Hamilton; Andrew Philp
Journal:  Biogerontology       Date:  2016-01-20       Impact factor: 4.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.